Updated: Jul 19
This recent press release details how reduced graphene oxide is being developed to control vagus nerve by INBRAIN Neuroelectronics.
See Dr T's video to connect the dots.
QUOTE: "...INBRAIN Neuroelectronics, a company at the intersection of medtech, deeptech and digital health dedicated to developing the world’s first graphene-based intelligent neuroelectronic system, today announced a collaboration with Merck, a leading science and technology company. The aim of the collaboration is to co-develop the next generation of graphene bioelectronic vagus nerve therapies targeting severe chronic diseases in Merck’s therapeutic areas through INNERVIA Bioelectronics, a subsidiary of INBRAIN Neuroelectronics.
“We aim to accelerate developments in the emerging field of bioelectronics by boosting the novel modality of selective neurostimulation,” said Laura Matz, Chief Science and Technology Officer of Merck. “Today’s agreement with INNERVIA Bioelectronics gives Merck access to a unique technology that increases energy efficiency in neurostimulators and could therefore become a true enabler for digital personalized treatment of patients suffering from severe and chronic diseases such as inflammatory disorders.”..."